Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 4/20 | 0.47 |
| ▸ | CNR1 | P21554 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5753712 | 1.00 | RAB9A (0.47) | RAB9APDE4BPDE4DCNR2CNR1 | |
| SCHEMBL8319888 | 0.91 | RAB9A (0.47) | RAB9APDE4BPDE4DCNR2CNR1 | |
| SCHEMBL5750322 | 0.91 | RAB9A (0.59) | RAB9ACNR2CNR1ALDH1A1MEN1 | |
| SCHEMBL5840316 | 0.90 | CNR2 (0.48) | RAB9APDE4BPDE4DCNR2CNR1 | |
| Hydrochloric Acid SCHEMBL5751702 | 0.90 | RAB9A (0.46) | RAB9APDE4BPDE4DCNR2CNR1 | |
| Hydrochloric Acid SCHEMBL5751698 | 0.90 | RAB9A (0.46) | RAB9APDE4BPDE4DCNR2CNR1 | |
| SCHEMBL5841455 | 0.89 | RAB9A (0.49) | RAB9APDE4BPDE4DCNR2CNR1 | |
| SCHEMBL5781437 | 0.88 | CNR2 (0.46) | RAB9APDE4BPDE4DCNR2CNR1 | |
| SCHEMBL5781444 | 0.88 | CNR2 (0.46) | RAB9APDE4BPDE4DCNR2CNR1 | |
| SCHEMBL5840651 | 0.88 | PDE4B (0.44) | RAB9APDE4BPDE4DCNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141586-B2 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1651609-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| US-20050032838-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. | 2005-02-10 | — | — | US | disclosed |
| WO-2005009966-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032838-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | CBR3, CBR1, PDE9A | RAB9A 1016/4885PDE4B 8/4885PDE4D 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.